Severe community-acquired pneumonia. Etiology, prognosis, and treatment. 1990

J Pachon, and M D Prados, and F Capote, and J A Cuello, and J Garnacho, and A Verano
Infectious Diseases Unit (Service of Internal Medicine), Virgen del Rocio University Hospital, Seville, Spain.

The frequency of community-acquired pneumonia coupled with its mortality rate of 10 to 25% is of growing concern to clinicians. A prospective study of 67 patients with severe community-acquired pneumonia was carried out to determine the causative agents, the impact fore-knowledge of the etiology has on the outcome, the value of clinical and radiologic criteria in predicting the evolution, and the efficacy of empirical therapy. The study group included 45 men and 22 women (mean age: 56.8 +/- 16.6 yr), and 46.2% suffered from a concurrent debilitating disease. The cause of pneumonia was diagnosed in 32 cases, and the most common pathogens were Streptococcus pneumoniae (37.5%), Legionella pneumophila (21.8%), and gram-negative bacilli (25.0%). The fact that fungal infections were present in three patients and Pneumocystis carinii in one are worthy of note. The overall death rate was 20.8%. A fatal outcome was related to the age of the patient (p less than 0.05), the presence of debilitating disease (p = 0.026), and septic shock (p = 0.0009). Diagnosis of the causative agents did not aid in increasing the survival rate, but it did allow for better patient management. Most of the patients (85.1%) initiated on treatment with erythromycin plus tobramycin recovered, but only 68.4% of the subjects commenced on treatment with other therapeutics survived. Furthermore, it was necessary to modify the therapy of a greater percentage of the latter group (p less than 0.025). Gram-negative bacillary pneumonia was a frequent finding among the patients who did not recover, making empirical treatment with erythromycin plus third generation cephalosporins most advisable for severe cases of community-acquired pneumonia.

UI MeSH Term Description Entries
D007877 Legionnaires' Disease An acute, sometimes fatal, pneumonia-like bacterial infection characterized by high fever, malaise, muscle aches, respiratory disorders and headache. It is named for an outbreak at the 1976 Philadelphia convention of the American Legion. Legionella pneumophila Infections,Infections, Legionella pneumophila,Legionnaire Disease,Pontiac Fever,Disease, Legionnaire,Disease, Legionnaires',Fever, Pontiac,Infection, Legionella pneumophila,Legionella pneumophila Infection,Legionnaire's Disease,Legionnaires Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D011018 Pneumonia, Pneumococcal A febrile disease caused by STREPTOCOCCUS PNEUMONIAE. Pneumococcal Pneumonia,Pneumococcal Pneumonias,Pneumonias, Pneumococcal
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002435 Cefamandole Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate. Cephamandole,Compound 83405
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D005260 Female Females

Related Publications

J Pachon, and M D Prados, and F Capote, and J A Cuello, and J Garnacho, and A Verano
January 2001, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
J Pachon, and M D Prados, and F Capote, and J A Cuello, and J Garnacho, and A Verano
September 1998, Infectious disease clinics of North America,
J Pachon, and M D Prados, and F Capote, and J A Cuello, and J Garnacho, and A Verano
August 1995, Chest,
J Pachon, and M D Prados, and F Capote, and J A Cuello, and J Garnacho, and A Verano
January 1988, Clinical therapeutics,
J Pachon, and M D Prados, and F Capote, and J A Cuello, and J Garnacho, and A Verano
October 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
J Pachon, and M D Prados, and F Capote, and J A Cuello, and J Garnacho, and A Verano
March 2002, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
J Pachon, and M D Prados, and F Capote, and J A Cuello, and J Garnacho, and A Verano
October 2021, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
J Pachon, and M D Prados, and F Capote, and J A Cuello, and J Garnacho, and A Verano
December 2001, Current opinion in infectious diseases,
J Pachon, and M D Prados, and F Capote, and J A Cuello, and J Garnacho, and A Verano
January 1985, Scandinavian journal of infectious diseases,
Copied contents to your clipboard!